{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Grade 3 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Grade 4 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5 TEAE (Death)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Treatment-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"TEAE leading to withdrawal"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Analysis of treatment-emergent adverse events (TEAEs) reported from clinical laboratory tests, physical examinations, and vital signs, with severity graded according to the NCI CTCAE, Version 4.0.","groups":[{"description":"Includes all subjects who received at least 1 immunization with study drug.","id":"OG000","title":"Safety Analysis Set"}],"paramType":"NUMBER","populationDescription":"The Safety Analysis Set comprises all subjects who received at least 1 immunization with study drug.","reportingStatus":"POSTED","timeFrame":"Continuously for up to 14 months","title":"Assessment of Safety of recMAGE-A3 + AS15","type":"PRIMARY","unitOfMeasure":"participants"}